Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Corporate Secretary 60 08/08/2019
Director TitleAgeSince
Director/Board Member 60 07/06/2019
Director/Board Member 49 21/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+3.23%+2.25%+65.02%+116.66% 5.45TCr
+0.04%+5.05%+43.44%+36.75% 4.39TCr
+3.86%+7.43%-11.83%-15.82% 2.26TCr
+2.83%+6.86%-2.09%+385.80% 2.07TCr
-0.53%-0.27%+12.68%-37.07% 1.58TCr
+5.27%+1.87%+13.67%-38.00% 1.48TCr
+1.65%+0.32%+27.55%+178.51% 1.31TCr
-5.17%+4.13%+13.12% - 1.27TCr
-0.38%+5.77%+78.29%+103.08% 1.16TCr
Average +1.08%+0.18%+26.65%+91.24% 2.33TCr
Weighted average by Cap. +1.65%+0.18%+33.26%+91.26%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!